Malaria is still today one of the deadliest infectious diseases affecting a huge proportion of
the world population, hitting with special virulence those people living in the least developed …

In order to counter the malarial parasite's striking ability to rapidly develop drug resistance, a
constant supply of novel antimalarial drugs and potential drug targets must be available. The …

The discovery of a plastid in apicomplexan parasites was hoped to be a watershed moment
in the treatment of parasitic diseases as it revealed drug targets that are implicitly divergent …

Dihydroorotate dehydrogenase (DHODH) mediates the fourth step of de novo pyrimidine
biosynthesis and is a proven drug target for inducing immunosuppression in therapy of …

The intracellular protozoan parasite Babesia gibsoni infects canine erythrocytes and causes
babesiosis. The hazards to animal health have increased due to the rise of B. gibsoni …

The quest for reliable dihydroorotate dehydrogenase (DHODH) inhibitors has engendered
the discovery of potential therapeutic compounds at different stages of clinical trials …

Malaria continues to be a global health threat, affecting approximately 219 million people in
2018 alone. The recurrent development of resistance to existing antimalarials means that …

Malaria remains a global public health burden with significant mortality and morbidity.
Despite the several approved drugs available for its management, the parasite has …

Malaria is a leading cause of human death within the tropics. The gradual generation of drug
resistance imposes an urgent need for the development of new and selective antimalarial …

The pyrimidine biosynthesis pathway in the protozoan pathogen Toxoplasma gondii is
essential for parasite growth during infection. To investigate the properties of dihydroorotate …